Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: A randomized controlled trial

Obstetrics and Gynecology

Volumn 114, Issue 5, 2009, Pages 999-1007

  McClung, Michael ^a   Miller, Paul ^a   Recknor, Chris ^a   Mesenbrink, Peter ^a   Bucci Rechtweg, Christina ^a   Benhamou, Claude Laurent ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE MASS; BONE TURNOVER; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; OSTEOLYSIS; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ABSORPTIOMETRY, PHOTON; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIUM; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; KINETICS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PLACEBOS; PROCOLLAGEN; VITAMIN D;

EID: 73549103391     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181bdce0a     Document Type: Article

References (36)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795
2. Miller RG. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture. Geriatrics 2006;61:24-30.
3. Brown JP, Josse RG, 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada [published errata appear in CMAJ 2003;168:400, CMAJ 2003;168: 676, and CMAJ 2003;168:544]. CMAJ. 2002;167 (10 Suppl): S1-34.
4. National Osteoporosis Foundation 2008. Available at: http://www.nof.org/ osteoporosis/diseasefacts.htm. Retrieved December 06, 2009.
5. 5. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-2822 (Pubitemid 33126923)
6. National Osteoporosis Foundation 2008. Available at: http://www.nof.org/ professionals/NOF-Clinicians-Guide.pdf. Retrieved July 11, 2009.
7. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998;128:253-261
8. 8. McClung M, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-386 (Pubitemid 43918197)
9. 9. McClung M, Recker R, Miller P, Fiske D, MinkoffJ, Kriegman A, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41:122-128 (Pubitemid 46901056)
10. Boccuzzi SJ, Folz SH, Omar MA, Kahler KH. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 2005;16 (Suppl 4):S35-6.
11. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822
12. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-1809
13. 13. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-1148 (Pubitemid 23261108)
14. 14. Tamhane AC, Hochberg Y, Dunnett CW. Multiple test procedures for dose finding. Biometrics 1996;52:21-37. (Pubitemid 26125088)
15. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York (NY): Wiley; 1987.
16. 16. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661 (Pubitemid 34815869)
17. 17. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687-694 (Pubitemid 30808808)
18. Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008;42:832-836
19. 19. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006;39:345-352 (Pubitemid 43851366)
20. 20. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20:1813-1819 (Pubitemid 41361882)
21. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, et al. Hip fracture in women without osteoporosis J Clin Endocrinol Metab 2005;90:2787-2793
22. Menopause and osteoporosis update 2009. http://www.sogc.org/guidelines/ documents/Menopause-JOGC-Jan-09.pdf. Retrieved July 11, 2009.
23. Drake WM, Kendler DL, Rosen CJ, Orwoll ES. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 2003;88:5759-5765
24. 24. Lenora J, Ivaska KK, Obrant KJ, Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007;18:1297-1305 (Pubitemid 47300283)
25. 25. Reginster JY, Deroisy R, Collete J, Albert A, Zegels B. Prediction of bone loss rate in healthy postmenopausal women. Calcif Tissue Int 1997;60:261-264 (Pubitemid 27106250)
26. 26. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res 1999;14:1614-1621 (Pubitemid 29416689)
27. 27. Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 2000;15:1398-1404 (Pubitemid 30413874)
28. 28. Garnero P, Munoz F, Sornay-Rendu E, Delmas PD. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007;40:716-722 (Pubitemid 46201944)
29. McClung MR. Osteopenia: to treat or not to treat? Ann Intern Med 2005;142:796-797
30. Watts NB. What is osteopenia, and what should be done about it? Cleve Clin J Med 2006;73:29-32.
31. Khosla S, Melton III LJ. Clinical practice. Osteopenia. N Engl J Med 2007;356:2293-2300
32. 32. Schousboe JT, NymanJA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005;142:734-741 (Pubitemid 40593775)
33. 33. Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health 2007;7:6. (Pubitemid 46767383)
34. 34. Chen YT, Miller PD, Barrett-Connor E, Weiss TW, Sajjan SG, Siris ES. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 2007;18:1287-1296 (Pubitemid 47300284)
35. Simon JA. Does osteopenia warrant treatment? Menopause 2005;12:639-648
36. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-236